RenovoRx announced that the Board of Directors has appointed Shaun Bagai as Chief Executive Officer and as an additional Member of the Board of Directors. Bagai brings more than 15 years of experience in the medical technology industry. Bagai joined RenovoRx in June 2014 and in his first few months has been preparing the company for the launch of the RenovoCath RC120.

Bagai previously lead Global Market Development for HeartFlow, Inc., where he managed HeartFlow's large clinical trial and led initial international market development and sales activities. Previously, Bagai was instrumental in developing the European market for renal denervation for Ardian, Inc. (acquired by Medtronic in 2011).